Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case- control study (CROSBI ID 303737)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Leke, Aminkeng Zawuo ; Dolk, Helen ; Loane, Maria ; Casson, Karen ; Nelen, Vera ; Barišić, Ingeborg ; Garne, Ester ; Rissman, Anke ; O’Mahony, Mary ; Neville, Amanda J. et al. Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case- control study // Reproductive toxicology, 100 (2021), 101-108. doi: 10.1016/j.reprotox.2021.01.006

Podaci o odgovornosti

Leke, Aminkeng Zawuo ; Dolk, Helen ; Loane, Maria ; Casson, Karen ; Nelen, Vera ; Barišić, Ingeborg ; Garne, Ester ; Rissman, Anke ; O’Mahony, Mary ; Neville, Amanda J. ; Pierini, Anna ; Bergman, Jorieke E.H. ; Klungsøyr, Kari ; Materna-Kiryluk, Anna ; Bielenska, Anna Latos ; Carbonell, Clara Cavero ; Addor, Marie-Claude ; Tucker, David

engleski

Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case- control study

This study investigated the risk of congenital heart defects (CHD) and other congenital anomalies (CA) associated with first trimester use of macrolide antibiotics (mainly erythromycin, spiramycin, clarithromycin and azithromycin) and lincosamides (clindamycin) using a case-malformed control design. Data included 145, 936 babies with a CA diagnosis (livebirths, stillbirths and terminations of pregnancy for CA) from 15 population-based EUROCAT registries in 13 European countries, covering 9 million births 1995- 2012. Cases were babies with CHD, anencephaly, orofacial clefts, genital and limb reduction anomalies associated with antibiotic exposure in the literature. Controls were babies with other CA or genetic conditions. Main outcomes were odds ratios adjusted (AOR) for maternal age and registry, with 95 % Confidence Intervals (95 %CI). Macrolide and lincosamide exposure was recorded for 307 and 28 cases, 72 and 4 non-genetic controls, 57 and 7 genetic controls, respectively. AOR for CHD was not significantly raised (AOR 0.94, 95 %CI: 0.70-1.26 vs non-genetic controls ; AOR 1.01, 95 %CI: 0.73-1.41 vs genetic controls), nor significantly raised for any specific macrolide. The risk of atrioventricular septal defect was significantly raised with exposure to any macrolide (AOR 2.98 ; 95 %CI: 1.48-6.01), erythromycin (AOR 3.68, 95 %CI: 1.28-10.61), and azithromycin (AOR 4.50, 95 %CI: 1.30-15.58). Erythromycin, clarithromycin, azithromycin, and clindamycin were associated with an increased risk of at least one other CA. Further research is needed on the risk of specific CA associated with macrolide and lincosamide use in the first trimester, particularly relevant for the potential use of azithromycin in the treatment of COVID-19.

Azithromycin ; Clarithromycin ; Clindamycin ; Congenital anomaly ; Erythromycin ; First trimester ; Macrolides ; Pregnancy ; Spiramycin

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

100

2021.

101-108

objavljeno

0890-6238

10.1016/j.reprotox.2021.01.006

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost